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Edited by Varda RotterAbstract In order to clarify the status of PCNA in normal and
transformed cells, we performed analysis of this protein by 2D-
PAGE, Western blot and mass spectrometry. All the cell lines
examined contained the major PCNA form (pI 4.57/30 kDa),
that is not post-translationally modiﬁed. In addition to the major
form, two minor isoforms (pI 4.52/30 kDa and pI 4.62/30 kDa)
were also detected in all the cell lines examined. However, the
level of PCNA in cancer cells is 5–6 folds higher than those in
primary and most of the immortalized cells. Taken together,
the signiﬁcant diﬀerence in PCNA status between cancer and
normal cells is not at the post-translational modiﬁcations but
in the overall levels of PCNA.
Crown Copyright  2007 Published by Elsevier B.V. on behalf of
the Federation of European Biochemical Societies. All rights
reserved.
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Proliferating cell nuclear antigen (PCNA) is involved in a
wide range of cellular functions including DNA replication, re-
pair and epigenetic maintenance, and is often used as a diag-
nostic and prognostic marker [1–4]. Accumulating lines of
evidence suggest that post-translational modiﬁcations, particu-
larly ubiquitination, may play a role in the regulation of
PCNA functions [5–7]. However, existence and functions of
other modiﬁcations are not completely clear, as published data
are often in conﬂict with one another [8–14].
Bechtel et al. [10] reported that primary and immortalized
breast (MCF10A) cells contained only a ‘‘very basic’’ form
of PCNA, while MCF7 and Hs578T breast cancer cell lines
contained only an ‘‘acidic’’ form. The MDA-MB468 breast
cancer cell line contained both the basic and acidic forms.
Although the authors did not accurately determine pH values,
the acidic and basic forms appear to be approximately pl 4.6Abbreviations: IEF, isoelectrofocusing; IPG, immobilized pH gradient;
2D-PAGE, two-dimensional polyacrylamide gel electrophoresis;
CHAPS, 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfo-
nate; ACN, acetonitrile; ABC, ammonium bicarbonate; CHCA, a-
cyano-4-hydroxycinnamic acid
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doi:10.1016/j.febslet.2007.09.022and pl 9.0, respectively. The authors suggested that this diﬀer-
ence in pI may be due to post-translational modiﬁcations [15].
Based on this initial observation, Malkas et al. [15] developed
polyclonal antibodies speciﬁc to ‘‘cancer-associated’’ PCNA
(caPCNA). If true, caPCNA could be an excellent biomarker
for cancer diagnosis. However, their published ﬁndings and
interpretation of the data raised a few questions such as: (1)
what kinds of post-translational modiﬁcations can change
pH from 4.6 to 9.0 without altering molecular weight, and
(2) why aren’t there any intermediate PCNA forms between
pI 4.6 and pI 9.0, if many modiﬁcations are involved? Also,
why has not the ‘‘basic isoform’’ been reported by any other
laboratories? These questions prompted us to systematically
examine the existence of a tumor-speciﬁc PCNA isoforms in
both cancer and ‘‘normal’’ cell lines.2. Materials and methods
2.1. Cells and cell culture
Cancer (MB 468, MCF-7, MDA-MB 231) and immortalized ‘‘nor-
mal’’ cell lines (CHO, MCF10A, 184B5, and Hs578Bst) were from
the American Type Cell Culture Collection (ATCC), and were grown
as described previously [13,16]. Human primary cells (HMEC) from
Cambrex/Lonza (Walkersville, MD) were grown according to the
manufacturer’s instructions.
2.2. Protein puriﬁcation and immunodetection
Recombinant human PCNA expressed in bacteria (BL21DE3)
transformed with pT7hPCNA was puriﬁed in the native form by chro-
matography on Sephacryl S200, MonoQ, and Superdex 200 10/300 GL
using a BioLogic HR instrument (BioRad, USA) as described previ-
ously [17,18]. Western blot analysis was also carried out as described
previously, with some modiﬁcations [16]. Brieﬂy, proteins were trans-
ferred from the gel to a PVDF membrane, Immobilon P (GE Health-
care, USA) using a Semi-Dry Blotter (BioRad). The membrane was
then soaked in methanol (1 min) and dried in oven (10 min, 37 C).
Without any blocking [19], the membrane was treated for 30 min with
an anti-PCNA antibody, PC10 (Santa Cruz, USA) diluted 1:2000 in
PBS containing 3% BSA. After washing in PBS, the membrane was
incubated for 20 min in a secondary, horseradish peroxidase-conju-
gated rabbit anti-mouse antibody (Sigma–Aldrich Canada Ltd.)
diluted 1:10000 in PBS containing 3% skim milk. The signal was pro-
duced by incubation in ECL, enhanced chemiluminescence, solution
(GE Healthcare) and captured by subsequent exposition on HT-L plus
ﬁlm (AGFA Corp, USA).
2.3. One- and two-dimensional gel electrophoresis
Analysis of samples by SDS–PAGE and two-dimensional polyacryl-
amide gel electrophoresis (2D-PAGE) was performed as described pre-
viously, with some modiﬁcations [12,16]. Brieﬂy, 2 M thiourea, an
eﬀective inhibitor of proteolysis [20], was added into a sample lysis
buﬀer (7 M urea, 2 M thiourea, 4% 3-[(3-chloroamidopropyl)f of theFederationofEuropeanBiochemical Societies.All rights reserved.
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immobilized pH gradient (IPG) buﬀer, pH 3–10 L, protease inhibitors
cocktail, 0.001% bromophenol blue) and a rehydration buﬀer (7 M
urea, 2 M thiourea, 2% CHAPS, 0.3% DTT, 2% IPG buﬀer (pH range
according to particular strips), 0.001% bromophenol blue). Several
types of immobilized pH gradient (IPG) gel strips, pH 3.0–10.0, 7-
cm; pH 4.0–7.0, 13-cm; pH 3.0–10.0, 13-cm; pH 4.0–5.0, 13-cm (GE
Healthcare) were used for the ﬁrst dimension. Isoelectrofocusing
(IEF) was conducted at 20 C using a MultiphorII unit (GE Health-
care). In the second dimension, SDS–PAGE was carried out using
apparatus S600 (GE Healthcare), or Hoefer miniVE vertical electro-
phoresis system.Fig. 1. Primary and immortalized cells generally contain low levels of
PCNA. (A) The extracts from asynchronous cell populations growing
in log phase (60–70% conﬂuence) were subjected to SDS–PAGE/
Western blot analysis as described in Section 2. Twenty micrograms of
protein were applied to each well of a 10% gel (Lanes 1–8; MB 468,
MCF10A, MB 231, Hs578Bst, HMEC, 184B5, MCF-7, CHO). After
SDS–PAGE and protein transfer to Immobilon P membrane, PCNA
was detected with the PC10 antibody (Santa Cruz) at 1:2000 dilution
and a secondary rabbit anti-mouse antibody (Sigma–Aldrich) at
1:10000 dilution. For a loading control, the same membrane was
treated with a rabbit anti-actin antibody (Sigma–Aldrich Canada2.4. PCNA mass spectrometry
After 2D-PAGE separation at a maximum resolution, the gel was
stained with Coomassie. The gel plugs (diameter 1 mm) containing
PCNA were cut out, destained for 15 min in 500 ll of 50% acetonitrile
(ACN) containing 25 mM ammonium bicarbonate, and shrunk by
incubation for 10 min in 200 ll of 100% ACN. ACN was removed
and the plugs were completely dried, using a Speed Vac (20 min).
The plugs were then rehydrated for 25 min in ice by adding 12 ll of
25 mM ammonium bicarbonate (ABC) containing either Trypsin Gold
(Promega, USA) (4 lg/ml), Lys-C (5 lg/ml), or Asp-N (10 lg/ml)
(Roche, Switzerland). The excess protease solution was replaced with
10 ll of 25 mM ABC and the protein was digested by incubation for
at least 4 h at 37 C. The produced peptides were mixed (1:1) with ma-
trix solution (CHCA (Fluka, Switzerland), 10 mg/ml, in 50% ACN,
0.1% triﬂuoroacetic acid), applied to the target plate, crystallized,
and analyzed by MALDI micro MX instrument (Waters Inc, USA).
Spectra were acquired in reﬂection mode using a total of 150 shots
in a random pattern across the spotted sample and further analyzed
using MasScot (http://www.matrixscience.com/search_form_select.
html), FindPep, or FindMod (http://ca.expasy.org/tools) software pro-
grams.Ltd.), 1:1000, and a secondary goat anti-rabbit antibody (Sigma–
Aldrich), 1:10000. The signal intensity of each band was quantiﬁed
using Phoretix 2D program (Nonlinear Inc, USA).3. Results and discussion
As shown in Fig. 1, primary epithelial cells (HMEC) and
two immortalized non-cancer cell lines (Hs578Bst and
184B5) showed very low level of PCNA. In contrast, three
breast cancer cell lines (MDA-MB 468, MDA-MB 231 and
MCF-7) showed 5-6-fold higher levels of PCNA than ‘‘nor-
mal’’ cells (Fig. 1). These data demonstrate that the elevated
level of PCNA is directly correlated to cell transformation,
although some immortalized cells also show high PCNA
expression (MCF10A and CHO cells; Fig. 1).
Next, we examined whether cancer cells contained diﬀerent
PCNA isoforms, relative to normal cells. Since we wanted to
observe proteins in a wide pH range, we used gel strips of
pH 3–10 (Fig. 2A). Data obtained by 2D-PAGE/Western blot-
ting with the anti-PCNA PC10 monoclonal antibody showed
the ‘‘acidic’’ form (pI 4.6) in all of the cells examined
(Fig. 2A). However, we could not detect the ‘‘basic’’ (pI 9.0)
form in any of the samples examined, including primary
human cells and MDA-MB 468 cells.
We then analyzed PCNA isoforms in more detail using a
higher resolution 2D-PAGE (IEF in pH 4–5 range, 18-cm long
IPG strips). As shown in Fig. 2B, PCNA from all of the cell
lines examined showed three isoforms at pI 4.52, 4.57 (major),
and 4.62 positions. This is consistent with our previous pub-
lished ﬁndings [13]. We have further analyzed the PCNA major
form by mass spectrometry, and did not ﬁnd any diﬀerence be-
tween cancer and primary cells (Fig. 3). Therefore, we con-
clude that there is no caPCNA or ‘‘non-malignant’’ PCNA
(nmPCNA) described by Bechtel et al. [10] and Malkas et al.
[15]. We found that the protein ﬁngerprints of major PCNAspots obtained from endogenous human PCNA (normal or
cancer cells) or from recombinant human PCNA expressed
in bacteria are basically the same. Using diﬀerent proteases,
we managed to cover 100% of the PCNA sequence by detected
peptide fragments (Fig. 3). As only technical modiﬁcations
(cysteine alkylation) were revealed around these fragments,
we conclude that the major spot of PCNA represents mainly
unmodiﬁed in vivo PCNA. This conclusion is consistent with
the fact that pI 4.57 of the PCNA major form is exactly the
same as human PCNA theoretical pI.
However, how might Bechtel et al. [10] have observed
caPCNA and nmPCNA? We propose the following explana-
tion as to why PCNA was erroneously detected at a very basic
position on 2D-PAGE. A very common problem associated
with IEF is a sample precipitation at the loading site [21]. Since
Bechtel et al. [10] used IEF in glass tubes and high concentra-
tion of NaOH (100 mM) for cathode electrolyte (upper buﬀer),
part of the sample might have precipitated after loading on the
top of the gel. These precipitated proteins would stay on the
top of the gel during IEF (ﬁrst dimension); however, they
might migrate and normally be resolved in the second dimen-
sion (SDS–PAGE). If this happens, one would detect PCNA at
the very basic position.
Furthermore, how could Malkas et al. [15] have ‘‘speciﬁ-
cally’’ detected caPCNA using their caPCNAab? The poly-
clonal antibodies generated by the group appear to be less
eﬃcient (have lower aﬃnity or titer) than commercially avail-
able PCNA antibodies (PC10, C20). Consequently, the caP-
CNAab might have detected PCNA in cancer cells, since
Fig. 3. Mass spectrometry suggests that the major part of PCNA is unmodiﬁed in vivo. Puriﬁed recombinant human PCNA or proteins from cells
(MB 468, HMEC or CHO) were separated by high resolution 2D-PAGE (18-cm DryStrip (pH 4–5) in the ﬁrst dimension and 10% gel slab in the
second). After separation, the gels were stained with Coomassie R350, the spots containing PCNA were cut out, and protein ﬁngerprint analysis was
carried out as described in Section 2. The produced spectra were analyzed by the MasScot, FindPep and FindMod programs. The area that was
covered by detected peptides is shown on the inserted PCNA sequence (bold underlined letters). Typical spectra generated by mass spectrometry after
digestion with diﬀerent proteases are shown.
Fig. 2. PCNA from primary, immortalized and cancer cells show the same migration pattern by 2D-PAGE. (A) Diﬀerent cells were solubilized in a
sample lysis buﬀer (0.2 mg of protein) and were then subjected to 2D-PAGE using 7-cm IPG strips (pH 3–10) for the ﬁrst dimension and 10% slab gel
(8.5 · 8.5 cm) for the second dimension (see Section 2). Subsequently, PCNA was detected by Western blotting with PC10 antibody.
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could not detect the low levels of PCNA in ‘‘normal’’ cells.Thus, it appears that the combination of the diﬀerent eﬃcien-
cies of the anti-PCNA antibodies and the diﬀerent protein
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derive an erroneous conclusion.
In summary, our comprehensive examination demonstrates
that there is no diﬀerence in PCNA post-translational modiﬁ-
cations between normal and cancer cells. The only signiﬁcant
diﬀerence between the two is that the protein level of PCNA
is several-fold higher in cancer cells. Since all the cell lines
examined have very similar proliferation rates (doubling time
is 30 h, except CHO cells (19 h)), our data raise an interest-
ing question whether high levels of PCNA contribute to, or are
a consequence of cell transformation.
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